Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer

DISEASE CHARACTERISTICS:

Histologically or cytologically confirmed localized adenocarcinoma of the prostate with one or more of the following:

Gleason sum at least 7
Prostate-specific antigen (PSA) at least 15 ng/mL
Clinical stage T2b or T2c (stage II)
Any combination of PSA, clinical stage, or Gleason sum with an estimated risk of capsular penetration greater than 45%
At least 3 positive core biopsies
Planned radical prostatectomy
No metastatic disease secondary to prostate cancer

PATIENT CHARACTERISTICS:

Age:

18 and over

Performance status:

ECOG 0-1

Life expectancy:

Not specified

Hematopoietic:

WBC greater than 3,000/mm^3
Platelet count greater than 100,000/mm^3
Hemoglobin greater than 9 g/dL
No history of bleeding disorders

Hepatic:

Bilirubin less than 1.5 mg/dL
AST/ALT less than 1.5 times upper limit of normal
No viral hepatitis

Renal:

Creatinine no greater than 1.5 mg/dL OR
Creatinine clearance at least 50 mL/min

Other:

No history of hypersensitivity and/or adverse reactions to salicylates
No allergy to sulfa-containing medications
No other active malignancy within the past 5 years except superficial bladder cancer or nonmelanoma skin cancer
No medical or psychiatric problem that would preclude study participation
No active infection
HIV negative

PRIOR CONCURRENT THERAPY:

Biologic therapy:

No prior immunologic therapy for prostate cancer

Chemotherapy:

At least 4 weeks since prior chemotherapy and recovered

Endocrine therapy:

No prior androgen ablation for prostate cancer
At least 4 weeks since prior hormonal therapy and recovered
At least 30 days since prior chronic use (more than 3 times per week for more than 2 weeks) of glucocorticoids
No concurrent glucocorticoids

Radiotherapy:

At least 4 weeks since prior radiotherapy to the pelvis or surrounding tissues and recovered

Surgery:

See Disease Characteristics
At least 4 weeks since prior major surgery and recovered

Other:

No prior investigational therapy for prostate cancer
No prior or concurrent chronic anticoagulants
No prior cyclo-oxygenase-2 inhibitor therapy (e.g., rofecoxib or celecoxib)
At least 4 weeks since prior initiation of vitamins (except multivitamin) or herbs with known effects on prostate function (PSA)
At least 30 days since prior chronic use (more than 3 times per week for more than 2 weeks) of aspirin (greater than 100 mg/day) or non-steroidal anti-inflammatory drugs (NSAIDs)

At least 24 hours since prior use and no concurrent use of any of the following:

Over-the-counter (OTC) or prescription products containing aspirin or NSAIDs; OTC products containing bismuth subsalicylate, sodium salicylate, and/or magnesium salicylate; choline salicylate; ranitidine; cimetidine; famotidine; or lansoprazole
No aspirin (100 mg/day) within 1 week prior to surgery
No concurrent addition of vitamins or herbal supplements